Back to results

FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX (GEMFOX)

Primary Purpose

Pancreatic Adenocarcinoma

Status

Recruiting

Phase

Phase 3

Locations

France

Study Type

Interventional

Intervention

Gemcitabine

FOLFOX

About this trial

This is an interventional treatment trial for Pancreatic Adenocarcinoma focused on measuring Pancreatic adenocarcinoma, Metastasis, Gemcitabine, FOLFOX, first-line

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Signed and dated informed consent, and willing and able to comply with protocol requirements,
Histologically or cytologically proven adenocarcinoma of the pancreas,
In absence of histologically or cytologically proven adenocarcinoma, a cluster of clinical, biological and radiological arguments consistent with the diagnosis: among these, a hypodense pancreatic tumor at CT and a Ca 19-9 greater than 500 UI/ml are essential prerequisites,
Metastatic disease confirmed (stage IV),
No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >12 months),
Age ≥18 years ,
Patient non-fit for FOLFIRINOX,
For patients with ECOG performance status (PS ) ≥2, an albuminemia level >25 g/l is required,
Haematological status: neutrophils (ANC) >2x109/L; platelets >100x109/L; haemoglobin ≥9g/dL,
Adequate renal function: serum creatinine level <150μM, and estimated creatinine clearance >30ml/min,
Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (≤5xULN in case of liver metastases),
Total bilirubin ≤3 x ULN,
QT / QTc interval at baseline ECG (performed within 1 month before randomization) < than 450 msec for men and < than 470 msec for women,
Baseline evaluations performed before randomization: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization,
Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test (β HCG) within 7 days prior to starting protocol treatment. Breastfeeding is not allowed.
Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment
Affiliation to a French social security system (recipient or assign).

Exclusion Criteria:

History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy),
Local or locally advanced disease (stage I to III),
Patient uses warfarin,
Patient receiving concomitant radiotherapy,
Electrolytic report uncontrolled: hypercalcemia and/or hypokalemia and/or hypomagnesemia,
Pre-existing permanent neuropathy (NCI grade ≥2 ),
Poor nutritional status
Known dihydropyrimidine dehydrogenase (DPD) total or partial deficiency (DPD activity dosage at inclusion visit),
Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
Treatment with any other investigational medicinal product within 28 days prior to study entry,
Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months),
Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C ,
Known uncontrolled bacterial infection
History or active interstitial lung disease (ILD),
Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
Patients with known allergy to active substance or any excipient of study drugs,
Allergy to iodinated contrast product
Concomitant administration of live, attenuated virus vaccine and concomitant administration of prophylactic phenytoin.
Patients under legal protection or unable to consent
Participation in another interventional research

Sites / Locations

APHP - Groupe Hospitalier Pitié-SalpêtrièreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Arm Label

Group I

Group II

Arm Description

Gemcitabine at 1000 mg/m²

Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²

Outcomes

Primary Outcome Measures

Overall survival (OS) at 24 months

OS will be defined as the delay between the date of inclusion and the date of death (whatever the cause) or the date of last news if the patient is alive.

Secondary Outcome Measures

Objective response rate

RECIST criteria 1.1 in case of evaluable lesion

Disease control rate

RECIST criteria 1.1 in case of evaluable lesion

Duration of response

The time interval between the first occurrence of partial or complete response according to RECIST criteria and secondary progression (clinic or radiologic)

Duration of disease control

The time interval between the first occurrence of disease control (stabilization or partial response or complete response) according to RECIST criteria and secondary progression (clinic or radiologic)

Progression Free Survival (PFS)

In most cases, patient will have a radiologic evaluation and radiologic progression will be defined according to RECIST criteria. In absence of radiologic evaluation (decision of investigator), clinic progression would be defined by investigators according to clinical deterioration of PS, increase of symptoms, and/or increase of tumor markers.

Carbohydrate antigen 19-9 (CA-19-9) and carcinoembryonic antigen (CEA) levels

Toxicities: Type, frequency and severity of adverse events and serious adverse events

Toxicities will be described and grades according to International Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Safety: Rate of serious adverse events, grade 3-4 toxicities (hematologic and non-hematologic)

Rate of serious adverse events, grade 3-4 toxicities (hematologic and non-hematologic). Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.

inLongitudinal changes in Quality of life (EORTC QLQ C-30 questionnaire and a consensual geriatric minimum data set (SOFOG) for patients ≥75 years)

Quality of life will be studied by means of the EORTC QLQ C-30 questionnaire (30 questions, score from 30 to 126) and a consensual geriatric minimum data set (SOFOG: 7 questions, score from 0 to 24) for patients ≥75 years at inclusion and at each cycle. A 5-point deterioration in HRQoL scores will be considered as the minimal clinically important difference (MCID). Time until MCID will be analyzed (for each questionnaire) and compared between the two groups. The dynamic change under treatment will be compared at each cycle.

Dose intensity of each protocol

The dose intensity (DI) of each protocol will be calculated based on the number of cycles received by each patient. The relative DI will be calculated as the ratio of the DI to the DI indicated in the protocol (obtained as the dose specified per cycle in mg/m²)

Quality-adjust Time Without Symptoms of disease or Toxicities (Q-TWiST)

The Q-TWiST method combines treatment benefits and risks into a single measure by partitioning survival time into three health states and subsequently assigning quality-of life weights to the survival time in each state. The primary Q-TWiST analysis will be performed using the Intention-to-treat analysis(ITT) population, and will be supplemented with analyses in the per-protocol population (i.e., patients who received ≥80% of the protocol-defined treatment during the first 6 weeks of treatment) and analysed in pre-specified subgroups: age (<75 years, ≥75 years), baseline PS (0-1, 2), liver metastases (Yes, No), and tumour location (head, other).

Rate of second and third line

For the patients who will stop the treatment of the protocol (for progression, toxicity or other reason...), we will register the date of beginning and of last administration of each new line of chemotherapy administered during the follow-up.

Full Information

NCT ID

NCT04167007

First Posted

August 28, 2019

Last Updated

August 17, 2020

Sponsor

Assistance Publique - Hôpitaux de Paris

1. Study Identification

Unique Protocol Identification Number

NCT04167007

Brief Title

FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

Acronym

GEMFOX

Official Title

Randomized Phase 3 Trial Comparing FOLFOX to Gemcitabine in Metastatic First-line in Patients With Pancreatic Adenocarcinoma and Non-fit for FOLFIRINOX

Study Type

Interventional

2. Study Status

Record Verification Date

August 2020

Overall Recruitment Status

Recruiting

Study Start Date

July 20, 2020 (Actual)

Primary Completion Date

July 2025 (Anticipated)

Study Completion Date

July 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

Pancreatic adenocarcinoma (PAC) incidence increases regularly in Western countries and it is expected to become the second leading cause of cancer-related mortality in 2020. The prognosis of this disease remains very poor with an overall 5-year survival rate less than 5%. The FOLFIRINOX regimen (5-fluorouracil [5-FU], folinic acid, irinotecan, and oxaliplatin) and the combination of nab-paclitaxel with gemcitabine demonstrated to be more effective than gemcitabine alone, and are both validated as standard first-line treatment options for metastatic PAC. However, the use of FOLFIRINOX is limited to patients with ECOG performance status (PS) 0-1 and aged less than 75 years. Nab-paclitaxel is currently not reimbursed in France.

Detailed Description

This trial is an open label, multicenter, randomized phase III trial comparing gemcitabine vs FOLFOX in patients with metastatic pancreatic adenocarcinoma and non-fit for FOLFIRINOX. Adults fulfilling inclusion criteria and non-inclusion criteria will be randomized between a FOLFOX arm and a gemcitabine arm. The primary endpoint is the overall survival (OS) at 24 months. The secondary objectives are : objective response rate and disease control rate (RECIST v1.1, in case of evaluable lesion), duration of response, duration of disease control, progression free survival (PFS), the evolution of biomarkers Ca 19-9 and CEA under treatment, the toxicities according to International Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, the safety of both arms, the quality of life, the dose intensity (DI) of each protocol, the Quality-Adjusted Survival, and the rate and type of second-line / third-line regimens chemotherapy. With an expected median survival time in the control group of 5 months, an accrual period of 3 years and a minimum follow-up period of 2 years, a total of 199 patients per group are required to detect a hazard ratio of 0.75 based on a 5% two-sided type I error rate and a power of 80%, leading to a total number of 400 patients to include.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pancreatic Adenocarcinoma

Keywords

Pancreatic adenocarcinoma, Metastasis, Gemcitabine, FOLFOX, first-line

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Group I

Arm Type

Active Comparator

Arm Description

Gemcitabine at 1000 mg/m²

Arm Title

Group II

Arm Type

Active Comparator

Arm Description

Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²

Intervention Type

Drug

Intervention Name(s)

Gemcitabine

Intervention Description

Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days

Intervention Type

Drug

Intervention Name(s)

FOLFOX

Intervention Description

Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.

Primary Outcome Measure Information:

Title

Overall survival (OS) at 24 months

Description

OS will be defined as the delay between the date of inclusion and the date of death (whatever the cause) or the date of last news if the patient is alive.

Time Frame

At 24 months after inclusion

Secondary Outcome Measure Information:

Title

Objective response rate

Description

RECIST criteria 1.1 in case of evaluable lesion

Time Frame

At 24 months after inclusion

Title

Disease control rate

Description

RECIST criteria 1.1 in case of evaluable lesion

Time Frame

At 24 months after inclusion

Title

Duration of response

Description

The time interval between the first occurrence of partial or complete response according to RECIST criteria and secondary progression (clinic or radiologic)

Time Frame

Tumor assessment will be done every 2 cycles (1cycle = 28 days), assessed up to 24 months after inclusion

Title

Duration of disease control

Description

Time Frame

Tumor assessment will be done every 2 cycles (1 cycle = 28 days), assessed up to 24 months after inclusion

Title

Progression Free Survival (PFS)

Description

Time Frame

From inclusion to the date of first event (progression or death) or date of last news if the patient is alive without progression, assessed up to 60 months

Title

Carbohydrate antigen 19-9 (CA-19-9) and carcinoembryonic antigen (CEA) levels

Time Frame

At baseline (at selection or inclusion visit before starting treatment) and then each 2 cycles (every 8 weeks) until end of treatment, up to 24 months

Title

Toxicities: Type, frequency and severity of adverse events and serious adverse events

Description

Toxicities will be described and grades according to International Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Time Frame

From inclusion to end of treatment, up to 24 months

Title

Safety: Rate of serious adverse events, grade 3-4 toxicities (hematologic and non-hematologic)

Description

Time Frame

From inclusion to end of treatment, up to 24 months

Title

inLongitudinal changes in Quality of life (EORTC QLQ C-30 questionnaire and a consensual geriatric minimum data set (SOFOG) for patients ≥75 years)

Description

Time Frame

At inclusion, before starting treatment, and then Day 1 of each cycle (every 4 weeks, 1 cycle = 28 days) until end of treatment, up to 24 months

Title

Dose intensity of each protocol

Description

Time Frame

During the entire treatment period, up to 24 months

Title

Quality-adjust Time Without Symptoms of disease or Toxicities (Q-TWiST)

Description

Time Frame

During the entire treatment period, up to 24 months

Title

Rate of second and third line

Description

Time Frame

From end of study treatment to patient death, assessed up to 60 months.

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Signed and dated informed consent, and willing and able to comply with protocol requirements, Histologically or cytologically proven adenocarcinoma of the pancreas, In absence of histologically or cytologically proven adenocarcinoma, a cluster of clinical, biological and radiological arguments consistent with the diagnosis: among these, a hypodense pancreatic tumor at CT and a Ca 19-9 greater than 500 UI/ml are essential prerequisites, Metastatic disease confirmed (stage IV), No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >12 months), Age ≥18 years , Patient non-fit for FOLFIRINOX, For patients with ECOG performance status (PS ) ≥2, an albuminemia level >25 g/l is required, Haematological status: neutrophils (ANC) >2x109/L; platelets >100x109/L; haemoglobin ≥9g/dL, Adequate renal function: serum creatinine level <150μM, and estimated creatinine clearance >30ml/min, Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (≤5xULN in case of liver metastases), Total bilirubin ≤3 x ULN, QT / QTc interval at baseline ECG (performed within 1 month before randomization) < than 450 msec for men and < than 470 msec for women, Baseline evaluations performed before randomization: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization, Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test (β HCG) within 7 days prior to starting protocol treatment. Breastfeeding is not allowed. Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment Affiliation to a French social security system (recipient or assign). Exclusion Criteria: History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy), Local or locally advanced disease (stage I to III), Patient uses warfarin, Patient receiving concomitant radiotherapy, Electrolytic report uncontrolled: hypercalcemia and/or hypokalemia and/or hypomagnesemia, Pre-existing permanent neuropathy (NCI grade ≥2 ), Poor nutritional status Known dihydropyrimidine dehydrogenase (DPD) total or partial deficiency (DPD activity dosage at inclusion visit), Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy), Treatment with any other investigational medicinal product within 28 days prior to study entry, Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months), Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C , Known uncontrolled bacterial infection History or active interstitial lung disease (ILD), Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years, Patients with known allergy to active substance or any excipient of study drugs, Allergy to iodinated contrast product Concomitant administration of live, attenuated virus vaccine and concomitant administration of prophylactic phenytoin. Patients under legal protection or unable to consent Participation in another interventional research

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Jean-Baptiste BACHET, MD, PhD

Phone

0142161041 / 0142161045

jean-basptiste.bachet@aphp.fr

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Jean-Baptiste BACHET, MD, PhD

Organizational Affiliation

Assistance Publique - Hôpitaux de Paris

Official's Role

Principal Investigator

Facility Information:

Facility Name

APHP - Groupe Hospitalier Pitié-Salpêtrière

City

Paris

ZIP/Postal Code

75013

Country

France

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jean-Baptiste BACHET, MD, PhD

jean-basptiste.bachet@aphp.fr

Phone

0142161041 / 0142161045

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

We'll reach out to this number within 24 hrs